Fundamental Analysis of ABCELLERA BIOLOGICS INC(NASDAQ:ABCL) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ABCL. ABCL was compared to 59 industry peers in the Life Sciences Tools & Services industry. ABCL has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, ABCL is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ABCL had negative earnings in the past year.

In the past year ABCL has reported a negative cash flow from operations.

In multiple years ABCL reported negative net income over the last 5 years.

Of the past 5 years ABCL 4 years had a positive operating cash flow.

1.2 Ratios

ABCL has a Return On Assets (-9.83%) which is in line with its industry peers.

ABCL has a Return On Equity (-12.70%) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-9.83%
ROE	-12.7%
ROIC	N/A

ROA(3y)4.03%

ROA(5y)2.91%

ROE(3y)5.04%

ROE(5y)1.61%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ABCL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ABCL has been increased compared to 1 year ago.

ABCL has more shares outstanding than it did 5 years ago.

There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.47 indicates that ABCL is not a great score, but indicates only limited risk for bankruptcy at the moment.

The Altman-Z score of ABCL (2.47) is comparable to the rest of the industry.

ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.47

ROIC/WACCN/A

WACC10.96%

2.3 Liquidity

A Current Ratio of 7.33 indicates that ABCL has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 7.33, ABCL belongs to the top of the industry, outperforming 86.44% of the companies in the same industry.

A Quick Ratio of 7.32 indicates that ABCL has no problem at all paying its short term obligations.

ABCL has a better Quick ratio (7.32) than 86.44% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.33
Quick Ratio	7.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ABCL have decreased strongly by -204.00% in the last year.

The Revenue for ABCL has decreased by -92.16% in the past year. This is quite bad

The Revenue has been growing by 34.00% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-204%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-70%

Revenue 1Y (TTM)-92.16%

Revenue growth 3Y-45.37%

Revenue growth 5Y34%

Revenue growth Q2Q-57.31%

3.2 Future

The Earnings Per Share is expected to grow by 16.83% on average over the next years. This is quite good.

The Revenue is expected to grow by 36.24% on average over the next years. This is a very strong growth

EPS Next Y-25.54%

EPS Next 2Y-16.48%

EPS Next 3Y-12.97%

EPS Next 5Y16.83%

Revenue Next Year25.45%

Revenue Next 2Y33.96%

Revenue Next 3Y28.75%

Revenue Next 5Y36.24%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ABCL. In the last year negative earnings were reported.

Also next year ABCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ABCL's earnings are expected to decrease with -12.97% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-16.48%

EPS Next 3Y-12.97%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ABCL does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (4/23/2024, 7:00:00 PM)

After market: 3.97 0 (0%)

3.97

-0.04 (-1%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.16B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-9.83%
ROE	-12.7%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.33
Quick Ratio	7.32
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-204%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-25.54%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-92.16%

Revenue growth 3Y-45.37%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ABCELLERA BIOLOGICS INC (ABCL)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens